Table 2 Inhibitory effect on the % GSK3β activity of 1,5-oxaza spiroquinone compounds (1a-c, 2a-r) and anti-inflammatory effect on LPS-induced BV-2 cells.

From: Positioning of an unprecedented spiro[5.5]undeca ring system into kinase inhibitor space

  1. a% GSK3β Residual Activity at 10 μM.
  2. bIC50 (GSK3β) was measured at ATP (1 μM).
  3. cIC50 value of each compound was defined as the concentration (μM) that caused 50% inhibition of NO production in LPS-activated BV-2 cells.
  4. dcell viability after treatment with 5 μM of each compound was determined by MTT assay, and it is expressed as a percentage (% of LPS). The results are averages of three independent experiments, and the data are expressed as the mean ± SD.
  5. eL-NMMA was positive control.
Back to article page